Telmisartan, Amlodipine and Combination in Healthy Subjects

Overview

To determine the pharmacokinetic profile of 80 mg telmisartan / 5 mg amlodipine (T80/A5) dose combination after single dose in healthy Chinese subjects. To determine whether a pharmacokinetic interaction exists between telmisartan and amlodipine, following single doses of 80mg telmisartan (T80), and 5 mg amlodipine (A5) tablet alone and in combination, in healthy Chinese subjects. To evaluate the safety and tolerability of T80 and A5 alone and in combination in healthy Chinese subjects.

Full Title of Study: “A Single-centre, Randomized, Open-label, Three-period Crossover Pharmacokinetic Study of 80 mg Telmisartan / 5 mg Amlodipine Fixed Dose Combination Compared With Its Monocomponents in Healthy Chinese Subjects”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: November 2010

Interventions

  • Drug: amlodipine/telmisartan/combination
    • patient would take amlodipine(5mg)/telmisartan(80mg)/combination(T80+A5mg) single dose in random order, and each dosage will be separated in 21 days interval.

Arms, Groups and Cohorts

  • Experimental: amlodipine/telmisartan/combination
    • all patients will be assigned to 6 treatment sequences. cross-over design was adopted to ensure each patient would take amlodipine/telmisartan/combination single dose in randomized order

Clinical Trial Outcome Measures

Primary Measures

  • Area Under the Concentration-time Curve of Telmisartan in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point (AUC_0-tz)
    • Time Frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
  • Area Under the Plasma Concentration-time Curve From the Time of Dosing to Infinity (AUC_0-∞) of Telmisartan
    • Time Frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
  • The Maximum Observed Plasma Concentration (Cmax) of Telmisartan
    • Time Frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
  • AUC_0-tz of Amlodipine
    • Time Frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
  • AUC_0-∞ of Amlodipine
    • Time Frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
  • Cmax of Amlodipine
    • Time Frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days of wash-outs

Secondary Measures

  • Time to Attain Cmax (Tmax) of Telmisartan
    • Time Frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
  • Terminal Rate Constant in Plasma (λz) of Telmisartan
    • Time Frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
    • reflect the speed of drug elimination in vivo
  • Mean Residence Time of Telmisartan in the Body After Oral Administration (MRT_po)
    • Time Frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
  • Elimination Half-life (t_½) of Telmisartan
    • Time Frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
  • Apparent Clearance of Telmisartan in Plasma Following Extravascular Administration (CL/F)
    • Time Frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
  • Apparent Volume of Distribution During the Terminal Phase λz Following an Extravascular Administration (V_z/F) of Telmisartan
    • Time Frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
  • Tmax of Amlodipine
    • Time Frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
  • λz of Amlodipine
    • Time Frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
  • MRT_po of Amlodipine
    • Time Frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
  • t_½ of Amlodipine
    • Time Frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
  • CL/F of Amlodipine
    • Time Frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
  • V_z/F of Amlodipine
    • Time Frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
  • Number of Participants With at Least One Treatment Emergent Adverse Event
    • Time Frame: 4 weeks
  • Number of Participants With Clinically Relevant Findings in Electrocardiogram (ECG), Vital Signs, Physical Finding or Laboratory Finding Abnormalities
    • Time Frame: 4 weeks

Participating in This Clinical Trial

Inclusion criteria 1. Healthy males and females 2. Aged between 18 and 45 years 3. Body weight more than 50Kg , and Body Mass Index (BMI ) between 19 and 24 kg/m2 Exclusion criteria 1. Any finding of the medical examination deviating from normal and of clinical relevance 2. Any evidence of a clinically relevant concomitant disease 3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders 4. Surgery of the gastrointestinal tract (except appendectomy) 5. Diseases of the central nervous system or psychiatric disorders or neurological disorders 6. History of relevant orthostatic hypotension, fainting spells or blackouts. 7. Chronic or relevant acute infections 8. History of relevant allergy/hypersensitivity (including allergy to drug or its excipients) 9. Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial 10. Use of drugs which might reasonably influence the results of the trial 11. Participation in another trial with an investigational drug within two months prior to administration or during the trial 12. Smoker 13. Inability to refrain from smoking during 24 hours prior to dosing and during the trial 14. Alcohol abuse or inability to stop alcoholic beverages for 24 hours prior to dosing and during the trial 15. Drug abuse 16. Blood donation (more than 100 mL within four weeks prior to administration or during the trial) 17. Excessive physical activities (within one week prior to administration or during the trial) 18. Any laboratory value outside the reference range that is of clinical relevance 19. Inability to comply with dietary regimen of trial site 20. A history of additional risk factors for torsade de pointes 21. Any history of relevant low blood pressure 22. Supine blood pressure at screening of systolic <110 mm Hg and diastolic < 60 mm Hg 23. History of urticaria 24. History of angioneurotic edema 25 Pregnancy / positive pregnancy test, or planning to become pregnant during the study or within 1 month of study completion 26. No adequate contraception during the study and until 1 month of study completion 27. Lactation period

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 45 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Boehringer Ingelheim
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Boehringer Ingelheim, Study Chair, Boehringer Ingelheim

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.